10 Results for "

FGFR3-IN-1

" in MedChemExpress (MCE) Product Catalog:
Products (10)

10 Results for "FGFR3-IN-1" in MCE Product Catalog:

Cat. No.: HY-147713
CAS No.: 2428743-04-6
Target:  

FGFR

Research Areas:  

Cancer

FGFR3-IN-1 (compound 1) is a fibroblast growth factor receptor (FGFR) inhibitor, with IC50s of 40 nM, 5.1 nM, and 12 nM for FGFR1, 2, and 3, respectively. FGFR3-IN-1 can be used for the research of bladder cancer .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-50905
CAS No.: 405169-16-6
Synonyms: CHIR-258; TKI258
Target:  

FLT3 c-Kit FGFR VEGFR PDGFR c-Fms

Research Areas:  

Cancer

Dovitinib (CHIR-258) is an orally active, potent multi-targeted tyrosine kinase (RTK) inhibitor with IC50s of 1, 2, 36, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, CSF-1R, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively. Dovitinib has potent antitumor activity .
loading...
    loading...
Cat. No.: HY-P991106
Synonyms: LY-3076226 antibody

Target:  

FGFR ADC Antibodies

Research Areas:  

Cancer

IMC-D11 (LY-3076226 antibody) is an anti-FGFR3 IgG1 monoclonal antibody with an EC50 of approximately 0.1 nM against hFGFR3b and hFGFR3c. IMC-D11 inhibits the growth of FGFR3-dependent lung adenocarcinoma in mouse models and shows no effect on tumors that do not express FGFR3. IMC-D11 can serve as an ADC Antibody for ADC synthesis, such as LY3076226. IMC-D11 is applicable to research related to urothelial carcinoma, multiple myeloma, lung adenocarcinoma, as well as advanced or metastatic cancers .
loading...
    loading...
Cat. No.: HY-145231
CAS No.: 2677709-81-6
Purity:  98.25%
Target:  

FGFR

Research Areas:  

Cancer

FGFR2-IN-2 (Compound 38) is a selective FGFR2 inhibitor with IC50s of 389, 29, and 758 nM for FGFR1, FGFR2, and FGFR3, respectively .
loading...
    loading...
Cat. No.: HY-50905R
CAS No.: 405169-16-6
Synonyms: CHIR-258 (Standard); TKI258 (Standard)
Research Areas:  

Cancer

Dovitinib (Standard) is the analytical standard of Dovitinib. This product is intended for research and analytical applications. Dovitinib (CHIR-258) is an orally active, potent multi-targeted tyrosine kinase (RTK) inhibitor with IC50s of 1, 2, 36, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, CSF-1R, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively. Dovitinib has potent antitumor activity .
loading...
    loading...
Cat. No.: HY-158011
CAS No.: 2446523-17-5
Target:  

FGFR

Research Areas:  

Cancer

FGFR3-IN-9 (example27) is a selective FGFR3 inhibitor .
loading...
    loading...
Cat. No.: HY-50905S
CAS No.: 1246819-84-0
Dovitinib-d8 is the deuterium labeled Dovitinib. Dovitinib (CHIR-258) is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively .
loading...
    loading...
Cat. No.: HY-158010
Target:  

FGFR

Research Areas:  

Cancer

FGFR3-IN-8 (example91) is a selective FGFR3 inhibitor .
loading...
    loading...
Cat. No.: HY-155028
CAS No.: 2658488-68-5
Target:  

FGFR

Research Areas:  

Cancer

FGFR-IN-11 (compound I-5) is an orally active and covalent FGFR inhibitor with IC50 values of 9.9 nM (FGFR1), 3.1 nM (FGFR2), 16 nM (FGFR3), and 1.8 nM (FGFR4), respectively. FGFR-IN-11 inhibits multiple cancer cell proliferation with nanomolar activity. FGFR-IN-11 inhibits tumor growth significantly in xenograft mice models .
loading...
    loading...
Cat. No.: HY-181153
Target:  

PROTACs FGFR

Research Areas:  

Cancer

PROTAC FGFR3 Degrader-1 is a fibroblast growth factor receptor 3 (FGFR3) PROTAC degrader, promotes FGFR3 degradation via the ubiquitin-proteasome pathway, and inhibits the downstream FGFR3/PI3K/AKT signaling pathway. PROTAC FGFR3 Degrader-1 can be used for the research of hepatocellular carcinoma .
loading...
    loading...